Treatment of classical Hodgkin lymphoma in young adults aged 18–30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012)

This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk‐stratified protocol in young adults (18–30 years) with classical Hodgkin Lymphoma. The primary end‐point was neurotoxicity rate. The incidence of grade 3 neurotoxicity was 11% (80% CI, 5–19%); a true...

Descripción completa

Detalles Bibliográficos
Autores principales: Townsend, William, Leong, Sarah, Hoskin, Peter, Diez, Patricia, Patrick, Pip, Linch, David, Wong, Wai‐Lup, Kayani, Irfan, Sanghera, Bal, Lopes, Andre, Daw, Stephen, Collins, Graham, Clifton‐Hadley, Laura, Ardeshna, Kirit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Haematological Malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154553/
https://www.ncbi.nlm.nih.gov/pubmed/31710702
http://dx.doi.org/10.1111/bjh.16296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154553/
https://www.ncbi.nlm.nih.gov/pubmed/31710702
http://dx.doi.org/10.1111/bjh.16296

Ejemplares similares